Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

ADME-Tox Screening System

By Drug Discovery Trends Editor | February 8, 2010

Hudson Robotics, Inc. introduced the VaryScreen ADME-Tox integrated workstation for profiling of the absorption, distribution, metabolism, and excretion (ADME) properties of drug molecules. VaryScreen ADME-Tox enables researchers to perform screens starting with just a single plate, yielding a complete profile more quickly and at a lower cost.

The basic VaryScreen ADME system contains everything needed to support biochemical assays that measure the physicochemical properties of a drug molecule (solubility, lipophilicity, pKa, protein binding). It supports PAMPA and CACO 2 permeability assays and can measure a drug’s affinity toward such key toxilogical targets as hERG and various CYP metabolic enzymes.

Controlled by Hudson Robotics’s SoftLinx scheduling software, VaryScreen ADME-Tox comes with sample protocols for each of the included ADME/Toxicity methods. The protocols are easily modified to meet user requirements, and more assays can be added to further customize follow-up screening efforts. VaryScreen ADME-Tox includes a multi-mode reader that not only supports the wide range of protocols, but also runs primary and secondary screens. This enables ADME/Tox profiling to be carried out automatically on hits found in the assays.

Hudson Robotics, Inc. 
 
 

 

 

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE